FL-411,2118944-88-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

FL-411

CAS No. : 2118944-88-8

MCE 国际站：FL-411

产品活性：FL-411 是一种有效的选择性 BRD4 抑制剂，抑制 BRD4(1)，IC₅₀ 为 0.43±0.09 μM。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vitro: FL-411 is a selective BRD4 inhibitor. Binding affinities of FL-411 are measured by TR-FRET against the first and second bromodomains of BRD2(1), BRD4(1), and BRD4(2) with IC₅₀s of 24.60±0.70 μM, 0.47±0.02 μM, 0.93±0.05 μM, respectively. FL-411 possesses a good BRD4(1) inhibition activity (IC₅₀=0.43±0.09 μM), antiproliferative activity (MCF-7, IC₅₀=1.62±0.06 μM; MDA-MB-231, IC₅₀=3.27±0.14 μM), and autophagic activity (42.29% in MCF-7 cells), as well as displays a low toxicity against MCF10A cells). FL-411 induces ATG5-dependent autophagy-associated cell death (ACD) by blocking BRD4-AMPK interaction and thus activating AMPK-mTOR-ULK1-modulated autophagic pathway in breast cancer cells.

In Vivo: To evaluate the antitumor activity of FL-411 in vivo, two breast tumor xenograft models, namely, MCF-7 and MDA-MB-231 cell lines models, are used. The in vivo study is conducted using three different doses of FL-411: 25 mg/kg, 50 mg/kg, and 100 mg/kg. In all the models, FL-411 shows significant tumor growth inhibition in a dose-dependent manner as determined by 80% and 76% tumor growth inhibition ratio in MCF-7 and MDA-MB-231 cell models, respectively. A remarkable loss of tumor weights is observed in all dose groups (p<0.001). FL-411 displays no obvious effects on the body weight of all the treatment groups. To examine whether FL-411-mediated inhibition of tumor growth in vivo is associated with reduced cell proliferation and the increased autophagy-associated cell death, tumor tissues from control and FL-411-treated mice are processed for the immunohistochemical analysis of Ki-67 and LC3. FL-411 treatment obviously reduces the number of Ki-67 (p<0.001) positive cells as well as increases autophagy levels, which is determined by increased LC3 expression (p<0.001).

相关产品：Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  (+)-JQ-1  |  Curcumin  |  A-485  |  C646  |  Revumenib  |  BRM/BRG1 ATP Inhibitor-1  |  BI 2536  |  dBET6  |  MZ 1  |  ARV-825  |  Inobrodib  |  Birabresib  |  666-15  |  SGC-CBP30  |  VTP50469  |  ACBI1  |  AU-15330  |  ARV-771  |  I-BET151  |  dBET1  |  dCBP-1  |  ABBV-744  |  Anacardic Acid  |  Molibresib  |  NSC 228155  |  KG-501  |  A-366  |  FHD-286  |  Mivebresib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds